Market Monitor - Chemicals performance - Belgium

Market Monitor

  • Belgia
  • Kjemikalier/Farmasøytisk

01 juni 2015

The Belgian chemicals sector is expected to grow in 2015, helped by a weaker euro, lower oil prices and a eurozone rebound.

Market performance snapshots

Belgium

  • Payments take 30 days on average
  • Growth expected to continue in 2015
  • Weakening competitiveness due to high labour costs

In international comparison, the Belgian chemicals sector benefits from a very high degree of specialisation. It includes a wide range of segments, from basic organic and inorganic products to pharmaceuticals, biotechnology, products for agriculture, paints, glues, detergents, cosmetics, rubber and plastics processing and many other specialty products such as chemicals for the photography industry. Chemicals (including pharmaceuticals) account for about 23% of the Belgian manufacturing sector, employing about 87,000 people directly and 144,000 people indirectly. More than 75% of the production is exported, and chemicals account for more than 30% of Belgian exports.

After growing in 2013, the Belgian chemicals sector continued its good performance in 2014. According to the Belgian chemicals association Essenscia, turnover increased 2.4% year-on-year in 2014, to EUR 64.2 billion, due to an increase in volumes as well as higher sales prices. In general, the chemicals sector was able to pass on higher raw materials and energy prices to end-customers. Investments amounted to EUR 1.78 billion (30% of total industrial investments in Belgium). Persistently high investments and high research and development spending are core strengths of this industry.

Compared to other Belgian sectors, the general equity, solvency and liquidity strengths of chemicals and pharmaceuticals companies continue to remain above average. Payments in the Belgian chemicals sector take 30 days on average. The number of payment delays is low, and expected to remain so in 2015. Insolvencies are expected to decrease further in 2015, however below the 6% decline forecast for all Belgian business insolvencies, given the already low number of insolvencies in the chemicals sector. Growth is expected to continue in 2015, helped by a weaker euro, lower oil prices and a eurozone rebound.

However, despite its structural resilience, the Belgian chemicals sector also has some weaknesses: competitiveness is weakening due to the fact that labour costs are among the highest in Europe and competition from China has increased. At the same time, the high export-dependency makes the Belgian chemicals sector susceptible to international risks, such as a potential further escalation of the crisis in Ukraine and the Middle East, a hard landing in China, or a return of the eurozone crisis (e.g. either by Greece leaving the eurozone or a deflationary spiral and liquidity trap).

That said, given the currently robust performance, financial health and low insolvency rate, our underwriting stance remains relaxed for the time being. Buyers are reviewed at least once a year on the basis of new accounts or when new information is received. The latest balance sheet is always requested and we also seek to obtain interim results from more sensitive buyers.

Relaterte dokumenter

Ansvarsfraskrivelse

Fremstillingene som er gitt her er kun generell informasjon, og skal ikke stoles på eller brukes som grunnlag for noe formål. Vennligst referer til selve polisen eller den aktuelle produkt- eller serviceavtalen for de styrende vilkårene. Ingenting i dette dokumentet skal tolkes til å skape noen rett, plikt eller ansvar fra Atradius' side, inkludert noen forpliktelse til å gjennomføre tilbørlig aktsomhet (due diligence) for kjøpere eller på dine vegne. Hvis Atradius gjennomfører tilbørlig aktsomhet for en kjøper, er det for egne underwriting-formål, og ikke til fordel for den forsikrede eller noen annen. I tillegg skal Atradius og tilhørende og tilknyttede selskaper og datterselskaper ikke i noe fall være ansvarlig for noen direkte, indirekte, spesielle eller tilfeldige skader eller følgeskader som følge av bruk av de fremstillinger som det er gitt informasjon om her.